"Pfizer and Novavax ink $530m vaccine delivery licensing deal" was originally created and published by Pharmaceutical ...

NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.

Four years into a Congressional probe of Big Pharma’s potential abuse of a 2017 tax break, Democratic lawmakers have homed in on Pfizer, accusing the New York drugmaker of some of the most egregious ...

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at ...

Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare ...